Ultragenyx: Q4 Earnings Snapshot

robot
Abstract generation in progress

Ultragenyx: Q4 Earnings Snapshot

Associated Press Finance

Fri, February 13, 2026 at 6:18 AM GMT+9 1 min read

In this article:

RARE

-1.59%

NOVATO, Calif. (AP) — NOVATO, Calif. (AP) — Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $129 million in its fourth quarter.

The Novato, California-based company said it had a loss of $1.29 per share.

The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1.20 per share.

The biotechnology company posted revenue of $207 million in the period, topping Street forecasts. Seven analysts surveyed by Zacks expected $202.9 million.

For the year, the company reported a loss of $575 million, or $5.83 per share. Revenue was reported as $673 million.


This story was generated by Automated Insights () using data from Zacks Investment Research. Access a Zacks stock report on RARE at

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin